cis-3-hydroxy-L-proline ethyl ester hydrochloride | 51814-20-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: cis-3-hydroxy-L-proline ethyl ester hydrochloride
• 英文别名: ethyl (2S,3R)-3-hydroxypyrrolidin-1-ium-2-carboxylate;chloride
• CAS: 51814-20-1
• 化学式: C₇H₁₃NO₃*ClH
• 分子量: 195.646
• InChiKey: KHKHSMQEXQMAOE-IBTYICNHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.31
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  63.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  cis-3-hydroxy-L-proline ethyl ester hydrochloride 在 吗啉 、 三丁基膦 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 20.0h， 生成 (-)-stephacidin A
  参考文献：
  名称：

  改进的D，L-stephacidin A的仿生全合成。

  摘要：

  已发现在Mitsunobu条件下将β-羟基脯氨酸衍生物直接转化为5-羟基吡嗪2（1H）-酮是生成IMDA中间体的一般仿生方法，已被用于D，L-的简洁，仿生总合成中Stephacidin A和D，L-brevianamideB。

  DOI：

  10.1021/ol701845t

文献信息

• Genome-Based Characterization of Two Prenylation Steps in the Assembly of the Stephacidin and Notoamide Anticancer Agents in a Marine-Derived <i>Aspergillus</i> sp.
  作者：Yousong Ding、Jeffrey R. de Wet、James Cavalcoli、Shengying Li、Thomas J. Greshock、Kenneth A. Miller、Jennifer M. Finefield、James D. Sunderhaus、Timothy J. McAfoos、Sachiko Tsukamoto、Robert M. Williams、David H. Sherman

  DOI：10.1021/ja1049302

  日期：2010.9.15

  products belong to a group of prenylated indole alkaloids containing a core bicyclo[2.2.2]diazaoctane ring system. These bioactive fungal secondary metabolites have a range of unusual structural and stereochemical features but their biosynthesis has remained uncharacterized. Herein, we report the first biosynthetic gene cluster for this class of fungal alkaloids based on whole genome sequencing of a marine-derived

  Stephacidin 和 notoamide 天然产物属于一组含有核心双环 [2.2.2] 重氮辛烷环系统的异戊二烯化吲哚生物碱。这些具有生物活性的真菌次级代谢物具有一系列不寻常的结构和立体化学特征，但它们的生物合成仍未得到表征。在此，我们报告了基于海洋衍生曲霉的全基因组测序的此类真菌生物碱的第一个生物合成基因簇。详细表征了催化正常和反向异戊二烯转移反应的两种中央途径酶。我们的研究结果确立了异戊二烯化吲哚生物碱结构的早期步骤，并提出了一种合成千金藤碱和诺托酰胺代谢物的方案。
• Biomimetic Total Synthesis of Malbrancheamide and Malbrancheamide B
  作者：Kenneth A. Miller、Timothy R. Welch、Thomas J. Greshock、Yousong Ding、David H. Sherman、Robert M. Williams

  DOI：10.1021/jo800116y

  日期：2008.4.1

  The biomimetic total syntheses of both malbrancheamide and malbrancheamide B are reported. The synthesis of the two monochloro species enabled the structure of malbrancheamide B to be unambiguously assigned. The syntheses each feature an intramolecular Diels−Alder reaction of a 5-hydroxypyrazin-2(1H)-one to construct the bicyclo[2.2.2]diazaoctane core, which has also been proposed as the biosynthetic

  报道了 malbrancheamide 和 malbrancheamide B 的仿生全合成。两种一氯物质的合成使得 Malbrancheamide B 的结构能够被明确指定。这些合成均以 5-羟基吡嗪-2(1 H )-one 的分子内 Diels-Alder 反应为特征，以构建双环[2.2.2]二氮杂辛烷核心，这也被提议作为这些化合物的生物合成途径。
• Aza-peptide macrocyclic hepatitis C serine protease inhibitors
  申请人：Wu X. H. Frank

  公开号：US20050065073A1

  公开（公告）日：2005-03-24

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式 I 化合物或其药学上可接受的盐、酯或原药： 其可抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A 蛋白酶的活性。因此，本发明的化合物可干扰丙型肝炎病毒的生命周期，也可用作抗病毒药物。本发明进一步涉及包含上述化合物的药物组合物，用于给丙型肝炎病毒感染者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者感染 HCV 的方法。
• A Concise, Biomimetic Total Synthesis of Stephacidin A and Notoamide B
  作者：Thomas J. Greshock、Alan W. Grubbs、Sachiko Tsukamoto、Robert M. Williams

  DOI：10.1002/anie.200604378

  日期：2007.3.19
• Aza-peptide macrocyclic hepatitis c serine protease inhibitors
  申请人：Wu Frank

  公开号：US20070021330A1

  公开（公告）日：2007-01-25

  The present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt, ester, or prodrug, thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.